Status pages and timeline pages for investigational obesity compounds, built for questions where the answer changes as filings, readouts, and label decisions move.
Quick answer — 2026 obesity-pipeline approval status
Already FDA approved: semaglutide (Wegovy/Ozempic), tirzepatide (Zepbound/Mounjaro). Per-compound detail in the cards below or the 2026 master tracker.
This table separates regulatory status from clinical-trial status. It is written for research and filing context only; it is not medical advice, prescribing guidance, or a human-use instruction.
| Compound | Sponsor / programme | Status checked June 2, 2026 | Primary evidence signal |
|---|---|---|---|
| Retatrutide | Eli Lilly / TRIUMPH | Investigational; Phase 3 obesity topline reported; no NDA filed | TRIUMPH-1 reported 28.3% mean body-weight reduction at 80 weeks on 12 mg in sponsor topline data. |
| CagriSema | Novo Nordisk / REDEFINE | FDA NDA filed December 2025; decision pending | REDEFINE-1 and related Phase 3 material support the filing; REDEFINE-4 adds head-to-head context. |
| Survodutide | Boehringer Ingelheim / Zealand / SYNCHRONIZE | Investigational; Phase 3 programme active; no approval announced | SYNCHRONIZE-1 reported 16.6% mean body-weight reduction at week 76 in sponsor topline data. |
| Orforglipron / Foundayo | Eli Lilly / oral non-peptide GLP-1 | FDA approved April 1, 2026; UAE EDE approval reported in April 2026 | FDA label and Drugs@FDA record establish approved status and labelled tablet strengths. |
| Oral VK2735 | Viking Therapeutics / VENTURE oral | Investigational; Phase 2 oral formulation study listed on ClinicalTrials.gov | NCT06828055 tracks the oral dose-finding study; subcutaneous Phase 3 work is a separate programme. |
This hub is for pages that answer a single freshness-sensitive question: approved or not, filed or not, when the next decision window is, and which programme milestone matters most right now. The goal is clarity rather than speculation.
These pages are written to answer whether a compound is approved, filed, in trial, or still investigational before any regional availability framing enters the page.
The approval cluster works best when it stays linked to source rules, editorial policy, and the broader research hub.
Start here for the primary approval and trial pages that anchor the 2026 obesity-pipeline narrative.
The retatrutide cluster currently leads the pipeline: the retatrutide approval status page answers the binary question, while the TRIUMPH trial tracker follows the Phase 3 readouts and the retatrutide UAE clinical-trial context handles country-specific framing. For deeper mechanism reading, open the retatrutide triple-agonist profile. Cross-pipeline comparisons sit at the 2026 obesity-drug approval tracker.
Direct answer page for Retatrutide across FDA, EMA, and MoHAP contexts with the current filing window summarized plainly.
Single index for programme milestones, readout timing, and what matters most in the path from Phase 3 to filing.
Portfolio-level page that compares approved drugs, filing candidates, and late-stage programmes on a shared timeline.
Local-trials read on Retatrutide and related programmes for queries that mix compound status with UAE visibility.
These pages cover the neighbouring assets most often compared against Retatrutide in approval-intent searches.
NDA-status and decision-window page for the amylin plus GLP-1 combination in late-stage development.
Status page for the dual GLP-1 and glucagon agonist, with a tight view of SYNCHRONIZE milestones.
Approval-status page built around the oral non-peptide GLP-1 narrative and how it differs from injectable pipelines.
The decision-focused page for readers searching the exact approval outcome rather than the broader status question.
Status page for a newer oral-candidate query pattern that sits adjacent to Orforglipron search intent.
Direct answers to the most common 2026 obesity-pipeline approval questions, with deeper pages linked from each.
As of May 2026, FDA-approved obesity drugs include semaglutide (Wegovy/Ozempic, Novo Nordisk), tirzepatide (Zepbound/Mounjaro, Eli Lilly), and orforglipron (marketed as Foundayo, Eli Lilly) — the first oral non-peptide GLP-1. Retatrutide, CagriSema, Survodutide, and oral VK2735 remain investigational. Full timeline: 2026 obesity drug approval tracker.
No. Retatrutide (LY-3437943) is investigational as of May 2026 — not approved by the FDA, EMA, or UAE MoHAP, and no NDA has been filed. Lilly reported positive TRIUMPH-1 pivotal obesity topline on May 21, 2026 (28.3% mean weight loss at 80 weeks on 12 mg). Full status: is retatrutide approved?
Not yet approved, but Novo Nordisk filed the CagriSema (cagrilintide + semaglutide) NDA with the FDA in December 2025 following the REDEFINE Phase 3 programme — REDEFINE 1 (obesity) and REDEFINE 2 (T2D) read out in 2025. FDA decision is pending as of May 2026. Full status: is CagriSema approved?
No. Survodutide (BI 456906, Boehringer Ingelheim / Zealand Pharma) is investigational. Boehringer reported positive SYNCHRONIZE-1 Phase 3 obesity topline on April 28, 2026, with 16.6% mean weight loss at week 76; SYNCHRONIZE T2D and additional readouts are ongoing. No NDA filed as of May 2026. Full status: is Survodutide approved?
Yes — on two regulators. Orforglipron was FDA approved as Foundayo in 2026, becoming the first oral non-peptide GLP-1 receptor agonist on the US market. The UAE Emirates Drug Establishment (EDE) approved orforglipron in early April 2026, marking a regional shift toward oral obesity treatment. Eli Lilly is the sponsor. Detail: Foundayo / orforglipron FDA approved.
Eli Lilly has not announced a retatrutide NDA filing date. With TRIUMPH-1 pivotal obesity topline reported May 21, 2026, and TRIUMPH-2 and TRIUMPH-3 readouts expected later in 2026, a filing window is generally watched in the 6–12 months following the last pivotal readout, but Lilly has not confirmed timing. Tracker: TRIUMPH trial tracker.
Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) are registered with the UAE Ministry of Health and Prevention (MoHAP). Orforglipron (Foundayo) was approved by the UAE Emirates Drug Establishment (EDE) in early April 2026 — the first oral GLP-1 cleared for the UAE market. Retatrutide, CagriSema, Survodutide, and oral VK2735 are not registered in the UAE because they remain investigational worldwide. Regional context: UAE & GCC peptide guides · Orforglipron UAE price.
Approved means a regulator (FDA, EMA, MoHAP) has authorised the drug for marketing after reviewing efficacy and safety data — labelled prescribing is permitted. Investigational means the drug is still in clinical trials or under regulatory review; it cannot be marketed for human use until approval. Investigational compounds may be available for in-vitro research only under Research Use Only frameworks.
Approval trackers are most useful when they keep four signals separate: regulator action, sponsor filing, trial-registry status, and peer-reviewed publication. A compound can have strong Phase 3 topline data and still be investigational; a submitted NDA can be under review without an announced public decision date; and a published trial can describe research findings without changing legal market status.
For this hub, "approved" means a named regulator has authorized a marketed product or label. FDA approval is checked against FDA announcements, Drugs@FDA, and product labelling. Clinical development status is checked against sponsor releases and ClinicalTrials.gov records. Trial data are treated as research context, not as medical, diagnostic, treatment, veterinary, or human-use guidance. Remy Peptides uses this page to organize public evidence for readers tracking the obesity-drug pipeline; any investigational compound discussed here remains outside labelled commercial drug use unless and until a regulator says otherwise.
That distinction matters for retatrutide and survodutide. Both have late-stage data signals in 2026, but neither has an announced FDA approval or public NDA approval. Retatrutide's TRIUMPH-1 topline is a pivotal Phase 3 obesity signal from Lilly, while the earlier Phase 2 publication in New England Journal of Medicine remains the peer-reviewed anchor for mechanism and dose-response context. Survodutide's SYNCHRONIZE-1 topline adds a Phase 3 dual GLP-1/glucagon signal, while MASH-focused trials remain a separate development pathway. These are programme milestones, not permission statements.
CagriSema sits in a different bucket because Novo Nordisk has publicly reported a US filing. Filing status is not approval status: it means the sponsor has submitted an application package for regulatory review. The REDEFINE clinical programme, PubMed-indexed REDEFINE analyses, and ClinicalTrials.gov records explain the evidence base, while the page's status answer remains "pending" until an FDA decision is public. Orforglipron / Foundayo is the approved-status contrast case in this cluster because the FDA has published an approval announcement and label for the oral non-peptide GLP-1 product.
For Research Use Only sourcing decisions, the practical takeaway is narrower than the clinical pipeline story. Researchers should document the compound name, sponsor code, current regulatory status, trial identifier, batch identity, COA status, and institutional handling requirements before any in-vitro laboratory work. This page does not recommend, instruct, or imply use in humans or animals. It is an evidence map for tracking filings and trial milestones across Remy Peptides' research library.
Primary and registry sources used for the approval-status table and trial-context summaries.